A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor The primary objective is to determine the efficacy of dapoxetine (30/60 mg prn) compared with placebo after 12 weeks of treatment in prolonging IELT (intravaginal ejaculatory latency time) in men with...

• Country None
• organs None
• Specialty None

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects To investigate mean changes in Hepatic Triglyceride Content (HTGC) from baseline to week 6 and 12 by 1H-Magnetic Resonance Spectroscopy (MRS) in obese subjects treated with JNJ-16269110: 10 mg bid, 1...

• Country None
• organs None
• Specialty None

A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schizophrenia The primary objective of this study is to demonstrate that paliperidone palmitate is not less effective than risperidone LAI. The safety and tolerability of paliperidone palmitate in the treatment of ...

• Country None
• organs None
• Specialty None

A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110 The primary objective of this study is to evaluate the effect of 12-week treatment with JNJ-16269110 on the glycated hemoglobin (HbA1c) concentration in subjects with T2DM.

• Country None
• organs None
• Specialty None

A randomized, Double-Blind, Active-Controlled, Parallel-Group, Noninferiority, Multicenter Study of Ceftobiprole Medocaril Versus Cefepime With or Without Vancomycin in the Treatment of Subjects With Fever and Neutropenia To demonstrate the noninferiority of ceftobiprole compared with cefepime with or without vancomycin in subjects with fever and neutropenia with regard to clinical cure versus not cured, after completi...

• Country None
• organs None
• Specialty None

Number of Doses and Time to Onset Of Pain Relief (Analgesic Effect) Using the IONSYS™ System [Fentanyl Iontophoretic Transdermal System (40 µg)] To evaluate the precise dosing pattern of IONSYS system use in post operative patients

• Country None
• organs None
• Specialty None

A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stable Schizophrenia Protocol 37822681SCH2003; Phase IIa EudraCT Number: 2007-007669-20 The primary objective is to investigate the safety and tolerability of JNJ-37822681 administered as qd or bid following a dose titration in male and female patients with stable schizophrenia.

• Country None
• organs None
• Specialty None

A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY™ or Alternate Care The primary objective is to characterize the safety profile of PRILIGY when used in clinical practice to treat patients with premature ejaculation.

• Country None
• organs None
• Specialty None

A Randomised, double blind, Placebo controlled, double dummy, parallel group, multicentre, dose ranging study in subjects with T2DM to evaluate the efficacy, safety, and tolerability of orally administered SGLT2 inhibitor JNJ-28431754 with Sitagliptin as a reference arm The primary objective of this dose-ranging study is to evaluate the effects of JNJ-28431754 as compared with placebo on the change in hemoglobin A1c (A1C) from baseline to Week 12 in subjects with T2D...

• Country None
• organs None
• Specialty None

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study to Investigate the Safety and Efficacy of JNJ-16269110 in Overweight and Obese Subjects The primary objective of the study is to find the appropriate, clinically relevant dosages (among the 5, 10, and 15 mg twice-daily dosages) of JNJ-16269110 by assessing mean changes in body weight fro...

• Country None
• organs None
• Specialty None